MedPharm, a Contract Development and Manufacturing Organisation (CDMO) specialising in topical and transdermal drug products, has become an Olink Certified Service Provider (CSP), making it the first Olink CSP in the Carolinas and one of only three in the Southeastern United States.

The certification enables MedPharm to provide Olink proteomic analysis across multi-species samples and multiple biological matrices, including tissue, plasma, serum and tears. The capability is designed to support pharmaceutical and biotechnology companies throughout the drug development process, from early-stage research to clinical development.

The addition of Olink's proteomics technology complements MedPharm's existing capabilities in disease modelling and human tissue-based research. By integrating proteomic analysis with reconstructed and ex vivo human tissue models, the company aims to provide clients with deeper insights into how therapeutic candidates influence human tissues at a functional level.

For drug developers, the integrated approach can help connect proteomic data with established disease models, offering a broader assessment of therapeutic activity and enabling researchers to investigate biological responses and potential mechanisms of action in human-relevant systems.

The Olink platform is based on Proximity Extension Assay (PEA) technology, which uses dual-antibody recognition of target proteins combined with a DNA-based readout.

PEA enables sensitive measurement of protein biomarkers from sample volumes as small as 1 microlitre, supporting both absolute and relative protein measurements across targets with varying levels of abundance.

The technology gives MedPharm an additional analytical capability that can be integrated with its existing human-relevant testing platforms, potentially helping sponsors evaluate therapeutic responses and biomarker profiles during drug development.

With operations in both the United States and United Kingdom, alongside a partnership network in Belgium, MedPharm is positioned to support clients across international markets as it expands its proteomic and human-relevant testing services.

MedPharm provides end-to-end contract services for topical and transepithelial products, covering early-stage research, formulation development, in vitro testing, clinical manufacturing and commercial manufacturing.

Following its 2024 merger with Tergus Pharma, MedPharm expanded its capabilities and scale, creating an integrated platform spanning drug development and formulation through large-batch commercial manufacturing and distribution.